Optimization of Lovastatin Self-Nanoemulsifying Solid Dosage Form.

Authors

  • Sanjay S. Patel Department of Pharmaceutics, Shri B. M. Shah College of Pharmaceutical Education and Research, Modasa, (Gujarat, India).
  • Sanjay S. Patel Department of Pharmaceutics, Shri B. M. Shah College of Pharmaceutical Education and Research, Modasa, (Gujarat, India).

Keywords:

Box-Behnken Design, Lovastatin, Zeta Potential, Surface Response Plot

Abstract

Aim: The aim of present study was to develop and optimized self-nanoemulsifying solid dosage form (SNESDF) of Lovastatin for enhancing its solubility. Lovastatin (whose water solubility is 0.4 x 10-3 mg/mL) is considered to be a reasonable drug because of its high log P value (4.3) and good solubility in oils.Materials and Methods: The formulations were optimized by Box-Behnken statistical design in which the independent variables like Ratio of surfactant: co-surfactant (X1), oil: surfactant co surfactant (X2), and % Aerosil (X3). The formulations were characterized for its dependent variables such as Droplet size (Y1), transmittance (Y3), percentage of drug released within 5 minutes (Y3), and within 15 minutes (Y4).Results and Conclusion: Droplet size and zeta potential of the optimized batch was found to be 21.89 nm and -6.4 mV, respectively. 44.32 % and 90.78 % of the drug was found to be released within 5 min and 15 min, respectively. Hence, by formulating into SNESDF, the solubility of Lovastatin was found to be significantly improved.

Downloads

Download data is not yet available.

References

Dahan A, Hoffman A. Rationalizing the selection of oral lipid based drug delivery systems by an in vitro dynamic lipolysis model for improved oral bioavailability of poorly water soluble drugs. J Control Release. 2008; 129(1): 1-10.

Nazzal S, Khan MA. Response surface methodology for the optimization of ubiquinone self-nanoemulsified drug delivery system. AAPS PharmSciTech. 2002; 3(1): 23-31.

Pouton CW. Lipid formulations for oral administration of drugs: non-emulsifying, self-emulsifying and ‘self-microemulsifying’ drug delivery systems. Eur J Pharm Sci. 2000; 11(Suppl 2): S93-8.

Hamed E, Sakr A. Application of multiple response 4. optimization technique to extended release formulations design. J Control Release. 2001; 73(2-3): 329-38.

Box GEP, Wilson KB. On the experimental attainment of 5. optimum multifactorial conditions. J Roy Statist Soc. 1951; 13: 1-15.

Khan MA, Dib J, Reddy IK. Statistical optimization 6. of Ketoprofen Eudragit S100 coprecipitates to obtain controlled-release tablets. Drug Dev Ind Pharm. 1996; 22(2): 135-41.

Box GEP, Behnken DW. Some new three level designs for 7. the study of quantitative variables. Technometrics. 1960; 2(4): 455-75.

Palamakula A, Mohammad TH, Khan MA. Response 8. surface methodology for optimization and characterization of limonene-based coenzyme Q10 self-nanoemulsified capsule dosage form. AAPS PharmSciTech. 2004; 5(4): 114-21.

Zhang P, Liu Y, Feng N, Xu J. Preparation and evaluation 9. of selfmicroemulsifying drug delivery system of oridonin. Int J Pharm. 2007; 355(1-2): 269-76.

Shen H, Zhong M. Preparation and evaluation of self-10. microemulsifying drug delivery systems (SMEDDS) containing atorvastatin. J Pharm Pharmacol. 2006; 58(9): 1183-91.

Kang BK, Lee JS, Chon SK, Jeong SY, Yuk SH, Khang G, 11. et al. Development of self-microemulsifying drug delivery systems (SMEDDS) for oral bioavailability enhancement of simvastatin in beagle dogs. Int J Pharm. 2004; 274(1-2): 65-73.

Downloads

Published

2013-03-20

How to Cite

1.
Patel SS, Patel SS. Optimization of Lovastatin Self-Nanoemulsifying Solid Dosage Form. Ars Pharm [Internet]. 2013 Mar. 20 [cited 2024 Jul. 22];54(1):7-15. Available from: https://revistaseug.ugr.es/index.php/ars/article/view/4576

Issue

Vol. 54 No. 1 (2013)

Section

Original Articles

License

The articles, which are published in this journal, are subject to the following terms in relation to the rights of patrimonial or exploitation:

  1. The authors will keep their copyright and guarantee to the journal the right of first publication of their work, which will be distributed with a Creative Commons BY-NC-SA 4.0 license that allows third parties to reuse the work whenever its author, quote the original source and do not make commercial use of it.

b. The authors may adopt other non-exclusive licensing agreements for the distribution of the published version of the work (e.g., deposit it in an institutional telematic file or publish it in a monographic volume) provided that the original source of its publication is indicated.

c. Authors are allowed and advised to disseminate their work through the Internet (e.g. in institutional repositories or on their website) before and during the submission process, which can produce interesting exchanges and increase citations of the published work. (See The effect of open access).